Literature DB >> 27747081

Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape.

Tanios Bekaii-Saab1, Bassel El-Rayes2.   

Abstract

Entities:  

Year:  2016        PMID： 27747081      PMCID： PMC5056257          DOI： 10.21037/jgo.2016.09.09

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


× No keyword cloud information.
  8 in total

1.  An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.

Authors:  Maeve A Lowery; David P Kelsen; Zsofia K Stadler; Kenneth H Yu; Yelena Y Janjigian; Emmy Ludwig; David R D'Adamo; Erin Salo-Mullen; Mark E Robson; Peter J Allen; Robert C Kurtz; Eileen M O'Reilly
Journal:  Oncologist       Date:  2011-09-20

2.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

3.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Authors:  Andrea Sartore-Bianchi; Livio Trusolino; Cosimo Martino; Katia Bencardino; Sara Lonardi; Francesca Bergamo; Vittorina Zagonel; Francesco Leone; Ilaria Depetris; Erika Martinelli; Teresa Troiani; Fortunato Ciardiello; Patrizia Racca; Andrea Bertotti; Giulia Siravegna; Valter Torri; Alessio Amatu; Silvia Ghezzi; Giovanna Marrapese; Laura Palmeri; Emanuele Valtorta; Andrea Cassingena; Calogero Lauricella; Angelo Vanzulli; Daniele Regge; Silvio Veronese; Paolo M Comoglio; Alberto Bardelli; Silvia Marsoni; Salvatore Siena
Journal:  Lancet Oncol       Date:  2016-04-20       Impact factor: 41.316

Review 4.  Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Authors:  Filippo Pietrantonio; Fausto Petrelli; Andrea Coinu; Maria Di Bartolomeo; Karen Borgonovo; Claudia Maggi; Mary Cabiddu; Roberto Iacovelli; Ilaria Bossi; Veronica Lonati; Mara Ghilardi; Filippo de Braud; Sandro Barni
Journal:  Eur J Cancer       Date:  2015-02-09       Impact factor: 9.162

5.  Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.

Authors:  Ramesh K Ramanathan; Jimmy J Hwang; William C Zamboni; Frank A Sinicrope; Howard Safran; Michael K Wong; Martin Earle; Adam Brufsky; Terry Evans; Monica Troetschel; Christine Walko; Roger Day; Helen X Chen; Sydney Finkelstein
Journal:  Cancer Invest       Date:  2004       Impact factor: 2.176

6.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Authors:  Timothy J Price; Marc Peeters; Tae Won Kim; Jin Li; Stefano Cascinu; Paul Ruff; Atilli Satya Suresh; Anne Thomas; Sergei Tjulandin; Kathy Zhang; Swaminathan Murugappan; Roger Sidhu
Journal:  Lancet Oncol       Date:  2014-04-14       Impact factor: 41.316
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.